Altana Pharma Ag

Byk Gulden Lomberg Chemische Fabrik Gmbh

Nycomed Gmbh

Takeda Gmbh

Katairo Gmbh

Ernst Sturm

Beate Schmidt

Guido Hanauer

Wolf-Rüdiger Ulrich

Jorg Senn-Bilfinger

Jörg Senn-Bilfinger

Wilm Buhr

Bernhard Kohl

Georg Rainer

Klaus Eistetter

Michael W Burnet

Rolf-Peter Hummel

J&ouml;rg Senn-Bilfinger

Bernd Müller

Ulrich Schraermeyer

Wolfgang-Alexander Simon

Reinhard Huber

Wolfgang Kromer

Stefan Postius

Michael Burnet

Bernd MÜLLER

Stefan Kaupp

A method for selecting a compound or a composition suitable for treating lipofuscin associated diseases in a patient, the method including the steps of determining a reactivity factor, determining a targeting factor that allows an uptake into a cell and a provides a targeting of lipofuscin, and selecting a compound or a composition or combining compounds to obtain a compound or composition that comprises a reactivity factor and an targeting factor.

Methods for the determination of compounds or compositions for the treatment of lipofuscin related diseases and compounds or compositions

The invention relates to (&#x2212;)-pantoprazole magnesium and its hydrates and to medicaments comprising these compounds.

Salt of (S)-pantoprazole and its hydrates

Novel surfactant protein C esters suitable for preparing pharmaceutical compositions for the treatment of infant respiratory distress syndrome and adult respiratory distress syndrome are described.

Surfactant protein C esters

Compounds of formula (I) in which the substituents as defined in the description are useful for preventing and treating gastrointestinal disorders.

Tricyclic imidazopyridines

Dialkoxypyridines of formula I ##STR1## wherein R1 is 1-3C-alkyl which is completely or predominantly substituted by fluorine, or a chlorodifluoromethyl radical and

Fluoroalkoxy substituted benzimidazoles useful as gastric acid secretion

Growing community of inventors

Constance, Germany

Ernst Sturm